| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christine L Wigen, Matthew B Goet. Serotonin syndrome and linezolid. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. vol 34. issue 12. 2002-06-20. PMID:12032904. |
we present a case of serotonin syndrome in a patient who initiated linezolid therapy shortly after discontinuation of therapy with a selective serotonin reuptake inhibitor (paroxetine). |
2002-06-20 |
2023-08-12 |
Not clear |
| Larry Culpeppe. Generalized anxiety disorder in primary care: emerging issues in management and treatment. The Journal of clinical psychiatry. vol 63 Suppl 8. 2002-06-11. PMID:12044106. |
the selective serotonin reuptake inhibitor (ssri) paroxetine is indicated for the short-term treatment of gad, although adequate data supporting the use of most ssris for gad are not yet available. |
2002-06-11 |
2023-08-12 |
Not clear |
| C Roberts, J Watson, G W Price, D N Middlemis. SB-236057-A: a selective 5-HT1B receptor inverse agonist. CNS drug reviews. vol 7. issue 4. 2002-06-10. PMID:11830759. |
this increase in 5-ht release was comparable to that observed after 14 days of paroxetine administration. |
2002-06-10 |
2023-08-12 |
human |
| I Scott Ramsey, Louis J DeFelic. Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor. The Journal of biological chemistry. vol 277. issue 17. 2002-05-31. PMID:11844791. |
5-ht, d-amphetamine, cocaine, and paroxetine inhibit transport more potently at lower expression levels; however, 5-ht potency for induction of current is similar at high and low expression. |
2002-05-31 |
2023-08-12 |
xenopus_laevis |
| Michael A Weitzner, Joanne Moncello, Paul B Jacobsen, Susan Minto. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. Journal of pain and symptom management. vol 23. issue 4. 2002-05-29. PMID:11997203. |
alternatives to hormone replacement, such as the use of the selective serotonin re-uptake inhibitor (ssri) paroxetine hydrochloride, are being explored as therapies for hot flashes in this patient population. |
2002-05-29 |
2023-08-12 |
Not clear |
| F Limosin, J Ade. [Psychiatric and psychological aspects of premenstrual syndrome]. L'Encephale. vol 27. issue 6. 2002-05-24. PMID:11865558. |
first studies showing serotonin re-uptake inhibitors efficiency in premenstrual dysphoric disorder were performed in the beginning of the nineties, with clomipramine and fluoxetine, and later fluvoxamine, paroxetine, sertraline and citalopram. |
2002-05-24 |
2023-08-12 |
Not clear |
| F Limosin, J Ade. [Psychiatric and psychological aspects of premenstrual syndrome]. L'Encephale. vol 27. issue 6. 2002-05-24. PMID:11865558. |
studies having compared the efficiency of antidepressants according to their serotonin activity (paroxetine or sertraline versus maprotiline, that is a selective noradrenaline re-uptake inhibitor), showed that serotonin re-uptake inhibitors were significantly more efficient on all symptoms than maprotiline, that was not more efficient than placebo. |
2002-05-24 |
2023-08-12 |
Not clear |
| Heidi L Liston, C Lindsay DeVane, David W Boulton, Samuel C Risch, John S Markowitz, Juliet Goldma. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. Journal of clinical psychopharmacology. vol 22. issue 2. 2002-05-13. PMID:11910262. |
the selective serotonin reuptake inhibitors (ssris) paroxetine, sertraline, and fluoxetine have varying degrees of potency in inhibiting the hepatic cytochrome p450 (cyp) 2d6 enzyme. |
2002-05-13 |
2023-08-12 |
human |
| M D Waldinger, A H Zwinderman, B Olivie. SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. Journal of clinical psychopharmacology. vol 21. issue 6. 2002-05-07. PMID:11763001. |
a double-blind, fixed-dose study in healthy men with lifelong rapid ejaculation was performed to evaluate potential differences between clinically relevant doses of two selective serotonin reuptake inhibitors, paroxetine and citalopram, in their effects on ejaculation. |
2002-05-07 |
2023-08-12 |
Not clear |
| Don R Cherek, Scott D Lane, Cynthia J Pietras, Joel L Steinber. Effects of chronic paroxetine administration on measures of aggressive and impulsive responses of adult males with a history of conduct disorder. Psychopharmacology. vol 159. issue 3. 2002-05-07. PMID:11862359. |
the role of serotonin in human aggression and impulsivity was evaluated by administering paroxetine or placebo for 3 weeks and comparing the effects on laboratory measures of aggression and impulsivity among male subjects with a history of conduct disorder. |
2002-05-07 |
2023-08-12 |
human |
| Kazuhiko Nakayam. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 365. issue 2. 2002-05-03. PMID:11819027. |
effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. |
2002-05-03 |
2023-08-12 |
rat |
| Kazuhiko Nakayam. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 365. issue 2. 2002-05-03. PMID:11819027. |
paroxetine, a selective serotonin (5-ht) reuptake inhibitor, increased extracellular 5-ht and dopamine levels, as determined by microdialysis, in the medial prefrontal cortex (mpfc) of freely moving rats. |
2002-05-03 |
2023-08-12 |
rat |
| Kazuhiko Nakayam. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 365. issue 2. 2002-05-03. PMID:11819027. |
there was a difference in the time course of the maximum response between the 5-ht and dopamine levels after paroxetine administration. |
2002-05-03 |
2023-08-12 |
rat |
| Kazuhiko Nakayam. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 365. issue 2. 2002-05-03. PMID:11819027. |
these results suggest that the increase in extracellular dopamine concentration in the mpfc elicited by paroxetine is the result of stimulation of 5-ht(3) receptors by the extracellular accumulation of 5-ht in the mpfc. |
2002-05-03 |
2023-08-12 |
rat |
| P Molander, A Thomassen, L Kristoffersen, T Greibrokk, E Lundane. Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma by temperature-programmed packed capillary liquid chromatography with on-column focusing of large injection volumes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 766. issue 1. 2002-05-02. PMID:11820298. |
a miniaturized temperature-programmed packed capillary liquid chromatographic method with on-column large volume injection and uv detection for the simultaneous determination of the three selective serotonin reuptake inhibitors citalopram, fluoxetine, paroxetine and their metabolites in plasma is presented. |
2002-05-02 |
2023-08-12 |
Not clear |
| Adamantios Serafeim, Gillian Grafton, Anita Chamba, Christopher D Gregory, Randy D Blakely, Norman G Bowery, Nicholas M Barnes, John Gordo. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood. vol 99. issue 7. 2002-05-02. PMID:11895792. |
5-ht receptor antagonists (sdz205-557, granisetron, methysergide) failed to inhibit serotonin-induced apoptosis, whereas the selective serotonin reuptake inhibitors (ssri)-fluoxetine (prozac), paroxetine (paxil), and citalopram (celexa)-substantially blocked the monoamine actions. |
2002-05-02 |
2023-08-12 |
Not clear |
| Cherri M Miner, Eileen B Brown, Jill S Gonzales, Reema Muni. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. The Journal of clinical psychiatry. vol 63. issue 3. 2002-04-24. PMID:11926723. |
this raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (ssris) such as citalopram, paroxetine, or sertraline. |
2002-04-24 |
2023-08-12 |
Not clear |
| Antona J Wagstaff, Susan M Cheer, Anna J Matheson, Douglas Ormrod, Karen L Go. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. vol 62. issue 4. 2002-04-23. PMID:11893234. |
paroxetine is a selective serotonin reuptake inhibitor (ssri), with antidepressant and anxiolytic activity. |
2002-04-23 |
2023-08-12 |
Not clear |
| Isabelle Loubinoux, Jérémie Pariente, Kader Boulanouar, Christophe Carel, Claude Manelfe, Olivier Rascol, Pierre Celsis, François Cholle. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage. vol 15. issue 1. 2002-03-20. PMID:11771971. |
a single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fmri study in healthy subjects. |
2002-03-20 |
2023-08-12 |
human |
| J A Schmitt, M J Kruizinga, W J Riede. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. Journal of psychopharmacology (Oxford, England). vol 15. issue 3. 2002-03-18. PMID:11565624. |
the current study was carried out to investigate the cognitive effects of two serotonin reuptake inhibitors (ssris), sertraline and paroxetine, with special reference to differences in their affinity for other neurotransmitter systems, i.e. |
2002-03-18 |
2023-08-12 |
human |